Temporary Assessment of Language in Kabuki Syndrome (TALK) Study

Speech and language development is a complex, multifactorial process driven by the individual’s ability to process and formulate communication. These processes can be interrupted in neurodevelopmental conditions. Redenlab are partnering with Boston Children’s Hospital on the Temporary Assessment of Language in Kabuki syndrome (TALK) study.

The TALK study is exploring speech and language patterns in individuals with Kabuki syndrome through a collaboration between the Roya Kabuki Program at Boston Children’s Hospital and Redenlab.

Prof Olaf Bodamer (Boston) and Profs Adam Vogel and Angela Morgan (Melbourne) are driving the study design and analysis with the aim of refining clinical trial outcome measures for clinical care and future trials.

Boston Children’s Hospital established a Kabuki Syndrome Program in 2017 to integrate the care, management, and treatment of children and adults with Kabuki syndrome and to conduct research aimed at identifying targeted therapies.

To find out more, and if you are interested in participating in this study, please click here.

Related Post

  • Posted on 31 March, 2024
    Speech and language impairments are core features of the neurodevelopmental genetic condition Kleefstra syndrome. The speech, language and cognitive profile...
    • Posted on 25 January, 2024
      MEDIA RELEASE Melbourne, 19 January 2024 — Redenlab, a leader in innovative healthcare solutions, ispleased to announce a groundbreaking study...
      • Posted on 25 January, 2024
        Exposing healthy adults to extended periods of wakefulness is known to induce changes in psychomotor functioning. The effect of fatigue...